Cooper B - Search Results

1

Lenalidomide, rituximab (R²), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.

Hill BT, Chen Y, Jagadeesh D, Dean R, Koc O, Boughan K, Cooper B, Pohlman B, Caimi P, Smith MR. Hill BT, et al. Among authors: cooper b. Leuk Lymphoma. 2024 Jun;65(6):768-773. doi: 10.1080/10428194.2024.2325636. Epub 2024 Mar 8. Leuk Lymphoma. 2024. PMID: 38456694 Clinical Trial.

2

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: cooper bw. Br J Haematol. 2016 May;173(3):404-12. doi: 10.1111/bjh.13975. Epub 2016 Mar 8. Br J Haematol. 2016. PMID: 26953041 Free article.

3

Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: cooper bw. Br J Haematol. 2016 Oct;175(2):275-280. doi: 10.1111/bjh.14228. Epub 2016 Jul 22. Br J Haematol. 2016. PMID: 27443247 Free article.

4

Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: cooper bw. Hematology. 2017 Aug;22(7):405-411. doi: 10.1080/10245332.2017.1279842. Epub 2017 Jan 20. Hematology. 2017. PMID: 28105889

5

Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia.

Wang J, de Lima M, Cooper BW, Boughan K, Metheny L, Otegbeye F, Caimi PF, Gallogly M, Malek E, Cao S, Fu P, Glotzbecker B, Schiltz NK, Tomlinson BK. Wang J, et al. Among authors: cooper bw. Leuk Lymphoma. 2021 Jun;62(6):1450-1457. doi: 10.1080/10428194.2020.1864350. Epub 2021 Jan 18. Leuk Lymphoma. 2021. PMID: 33461376

6

Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates.

Keenan M, Diamond A, Boughan K, Cooper B, Gallogly M, Malek E, Metheny L, O'Brien T, Otegbeye F, Tomlinson B, de Lima M, Caimi PF. Keenan M, et al. Among authors: cooper b. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):799-804. doi: 10.1016/j.clml.2021.06.015. Epub 2021 Jun 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34321189

7

Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines.

Diamond A, Ayyappan S, Cao S, Tashtish N, Boughan K, Cooper B, Fu P, Caimi PF. Diamond A, et al. Among authors: cooper b. Hematol Oncol. 2022 Oct;40(4):626-636. doi: 10.1002/hon.3034. Epub 2022 Jun 4. Hematol Oncol. 2022. PMID: 35644011

8

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.

Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW. Barr PM, et al. Br J Haematol. 2009 Oct;147(1):89-96. doi: 10.1111/j.1365-2141.2009.07836.x. Epub 2009 Jun 29. Br J Haematol. 2009. PMID: 19656151 Free PMC article. Clinical Trial.

9

Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.

Tandra A, Covut F, Cooper B, Creger R, Brister L, McQuigg B, Caimi P, Malek E, Tomlinson B, Lazarus HM, Otegbeye F, Kolk M, de Lima M, Metheny L. Tandra A, et al. Among authors: cooper b. Leuk Lymphoma. 2018 Jul;59(7):1644-1651. doi: 10.1080/10428194.2017.1390234. Epub 2017 Dec 4. Leuk Lymphoma. 2018. PMID: 29199482

10

Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.

Malek E, Gupta V, Creger R, Caimi P, Vatsayan A, Covut F, Bashir Q, Champlin R, Delgado R, Rondon G, Cooper B, de Lima M, Lazarus HM, Qazilbash M. Malek E, et al. Among authors: cooper b. Leuk Lymphoma. 2018 Aug;59(8):1905-1912. doi: 10.1080/10428194.2017.1408086. Epub 2018 Jan 2. Leuk Lymphoma. 2018. PMID: 29295650

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,735 results

Search Page